164. 眼皮膚白皮症 [臨床試験数:15,薬物数:57(DrugBank:34),標的遺伝子数:34,標的パスウェイ数:136

Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04193592
(ClinicalTrials.gov)
December 1, 20196/11/2019Efficacy and Safety of Pirfenidone Treatment in HPS-ILDPirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)Hermansky Pudlak Syndrome;Interstitial Lung DiseaseDrug: PirfenidoneJesse RomanGenentech, Inc.Not yet recruiting18 Years75 YearsAll50Phase 2United States;Puerto Rico
2NCT00001596
(ClinicalTrials.gov)
September 20053/11/1999Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak SyndromeTherapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak SyndromeAlbinism;Inborn Errors of Metabolism;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Pulmonary FibrosisDrug: Pirfenidone;Drug: PlaceboWilliam Gahl, M.D.National Human Genome Research Institute (NHGRI)Completed18 YearsN/AAll35Phase 2United States;Puerto Rico